[Form 4] Inhibikase Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

On 07/02/2025, Inhibikase Therapeutics, Inc. (ticker: IKT) submitted a Form 4 detailing an equity incentive granted to director Roberto Bellini. On 06/30/2025 he received a stock-option award for 108,176 common shares at an exercise price of $1.95 per share. The options vest on the earlier of 06/30/2026 or the day prior to the next annual shareholders’ meeting, provided Bellini remains on the board, and expire on 06/30/2032. The filing shows no open-market purchases or sales; the entire position is held directly and recorded at zero acquisition cost. Bellini’s post-transaction derivative holdings therefore total 108,176 options, with no change to his non-derivative share count.

Positive

• Director alignment: Stock-option grant incentivises long-term value creation by tying compensation to future share performance.
• Service commitment: Vesting condition requires Bellini’s continued board service until at least June 2026, supporting governance stability.

Negative

• Potential dilution: Exercise of 108,176 options would increase outstanding shares, marginally diluting existing holders.
• No cash purchase: Grant does not represent insider buying with personal funds, limiting bullish signaling value.

Insights

Financial Analyst

TL;DR: Routine option grant; aligns director incentives but limited immediate share-price impact.

The reported transaction is a standard non-cash director compensation grant that adds 108,176 options to Roberto Bellini’s holdings. Because the exercise price equals $1.95, economic value materializes only if IKT’s stock trades above that level before the 06/30/2032 expiry. While the grant strengthens management-shareholder alignment, it does not involve cash outlay or secondary-market activity, so near-term dilution is contingent on future exercise. For a small-cap biotech, the award size is modest and within typical board-compensation norms. Overall, the disclosure is neutral for valuation but does indicate Bellini’s intention to continue service through at least the next annual meeting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellini Roberto

(Last) (First) (Middle)

1000 N. WEST STREET, SUITE 1200

(Street)

WILMINGTON DE 19801

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inhibikase Therapeutics, Inc. [ IKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.95	06/30/2025		A		108,176		(1)	06/30/2032	Common Stock	108,176	$0	108,176	D

Explanation of Responses:

1. The options will vest on the earlier of June 30, 2026 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ David McIntyre, attorney-in-fact	07/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Inhibikase Therapeutics (IKT) report on 07/02/2025?

A Form 4 disclosed a grant of 108,176 stock options to director Roberto Bellini on 06/30/2025.

How many stock options were granted to Roberto Bellini?

He received 108,176 options for common stock.

What is the exercise price of Bellini’s new options?

The options can be exercised at $1.95 per share.

When will the options vest?

They vest on the earlier of 06/30/2026 or the day before the next annual shareholder meeting, subject to continued service.

When do the options expire?

The options expire on 06/30/2032.

Did the filing report any open-market share purchases or sales?

No. The Form 4 only records an option grant; no shares were bought or sold.